| Name | Title | Contact Details |
|---|
Founded in 2017, Unlearn.AI brings together a world-class team of experts across pharma, physics, machine learning, and business who share a vision of pioneering AI to eliminate trial and error in medicine. Unlearn is the only company creating TwinRCTsTM, which combine AI, prognostic digital twins, and novel statistical methods to run clinical trials requiring fewer patients in the control arm. Unlearn`s technology is used by leading global pharmaceutical companies, including Merck KGaA, Darmstadt, Germany, and has been published in conference abstracts and scientific journals, including Scientific Reports - Nature and The International Journal of Biostatistics. The European Medicines Agency qualifies Unlearn`s PROCOVA™ procedure, which provides the regulatory framework for the application of TwinRCTs to Phase 2 and 3 clinical trials.
ALX Oncology is a clinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Adgero Biopharmaceuticals Holdings, Inc. is a privately-held biopharmaceutical company focused on building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast cancer ("CMBC") who have failed radiation therapy. Use of Adgero`s existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.
Stellar Biotechnologies is a world leader in the development and manufacture of keyhole limpet hemocyanin (KLH).
MBio Diagnostics is now LightDeck Diagnostics! LightDeck Diagnostics believes in a new approach to healthcare, where fast, accurate, simple, low-cost diagnostic tests will be run wherever and whenever they are needed, without compromise. The company`s proprietary LightDeck® platform combines an advanced laser waveguide with novel materials and patented manufacturing techniques to deliver lab-quality results anywhere, in minutes. LightDeck is introducing a portfolio of in vitro diagnostic panels, the first is an on-the-spot test for COVID-19. The LightDeck platform is currently commercialized in veterinary diagnostics and for environmental testing. Learn more at www.LightDeckDx.com Platform Technology The LightDeck platform consists of a robust, portable fluorescence analyzer and disposable, multiplex test cartridges. The LightDeck® platform was designed to meet customer requirements: • Quality: Highly sensitive tests that deliver lab-quality results • Quick: Actionable data in as little as 5 minutes with a simple procedure • Quantitative: More data to inform treatment decisions • Multiplex: Multiple related tests for better precision plus internal quality control to maximize safety The test procedure is simple enough that an untrained user can perform testing almost anywhere. Panels can be configured to run multiple related tests simultaneously to help diagnosis or rule-out a specific condition. Internal quality control runs with every test to ensure quality and not report questionable results.